Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)

NCT01252199 is registered in ClinicalTrials.gov with Thallion Pharmaceuticals as lead sponsor.

NCT NCT01252199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01252199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)
Lead sponsor
Thallion Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
February 28, 2013
Enrollment
45 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

shiga toxin producing bacterial infection